The new landscape of retinal gene therapy

Cristy A. Ku, Mark E. Pennesi

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Novel therapeutics for inherited retinal dystrophies (IRDs) have rapidly evolved since groundbreaking clinical trials for LCA due to RPE65 mutations led to the first FDA-approved in vivo gene therapy. Since then, advancements in viral vectors have led to more efficient AAV transduction and developed other viral vectors for gene augmentation therapy of large gene targets. Furthermore, significant developments in gene editing and RNA modulation technologies have introduced novel capabilities for treatment of autosomal dominant diseases, intronic mutations, and/or large genes otherwise unable to be treated with current viral vectors. We highlight strategies currently being evaluated in gene therapy clinical trials and promising preclinical developments for IRDs.

Original languageEnglish (US)
Pages (from-to)846-859
Number of pages14
JournalAmerican Journal of Medical Genetics, Part C: Seminars in Medical Genetics
Issue number3
StatePublished - Sep 1 2020


  • RNA modulation
  • gene editing
  • gene therapy
  • inherited retinal dystrophies

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'The new landscape of retinal gene therapy'. Together they form a unique fingerprint.

Cite this